The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 29, 2022
Filed:
Oct. 23, 2015
Applicant:
Calidi Biotherapeutics, Inc., La Jolla, CA (US);
Inventors:
Aladar Szalay, Highland, CA (US);
Boris Minev, San Diego, CA (US);
Assignee:
Calidi Biotherapeutics, Inc., La Jolla, CA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61K 35/54 (2015.01); A61K 31/00 (2006.01); A61K 35/44 (2015.01); A61K 38/50 (2006.01); A61K 35/28 (2015.01); A61K 35/51 (2015.01); A61K 41/00 (2020.01); A61K 35/30 (2015.01); A61K 35/768 (2015.01); A61K 9/00 (2006.01); A61K 35/12 (2015.01); A61K 38/19 (2006.01); A61K 39/395 (2006.01); A61N 5/06 (2006.01); A61N 5/10 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01);
U.S. Cl.
CPC ...
A61K 39/0011 (2013.01); A61K 9/0019 (2013.01); A61K 31/00 (2013.01); A61K 35/12 (2013.01); A61K 35/28 (2013.01); A61K 35/30 (2013.01); A61K 35/44 (2013.01); A61K 35/51 (2013.01); A61K 35/54 (2013.01); A61K 35/768 (2013.01); A61K 38/19 (2013.01); A61K 38/50 (2013.01); A61K 39/39558 (2013.01); A61K 41/0038 (2013.01); A61K 45/06 (2013.01); A61N 5/062 (2013.01); A61N 5/10 (2013.01); C07K 16/2818 (2013.01); C07K 16/30 (2013.01); C12Y 305/01001 (2013.01); A61K 2039/5156 (2013.01); A61K 2039/572 (2013.01); A61N 2005/0661 (2013.01); A61N 2005/1098 (2013.01); C07K 2317/76 (2013.01);
Abstract
Disclosed herein are methods and compositions related to combination therapy for cancer. More specifically, several treatment modalities are used in combination to induce an effective anti-tumor immune response. The present invention relates generally to the treatment of human cancer and, more specifically, to use of several treatment modalities in combination to induce effective anti-tumor immune responses.